Moreover, elevated level of GLUT-1 transporter is linked to poor CD8+ effector T cells infiltration in the tumor, suggesting that targeting upregulation of GLUT-1 could improve immunotherapeutic efficacy and induce cancer cell death [141]. Here, SLC2A1 is linked to neoplasm.